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Summary
Community-associated methicillin-resistant Staphy-
lococcus aureus (CA-MRSA) is a threat to human
health worldwide. Although progress has been made,
mechanisms of CA-MRSA pathogenesis are poorly
understood and a comprehensive analysis of
CA-MRSA exoproteins has not been conducted. To
address that deﬁciency, we used proteomics to
identify exoproteins made by MW2 (USA400) and
LAC (USA300) during growth in vitro. Two hundred
and ﬁfty unique exoproteins were identiﬁed by
2-dimensional gel electrophoresis coupled with auto-
mated direct infusion-tandem mass spectrometry
(ADI-MS/MS) analysis. Eleven known virulence-
related exoproteins differed in abundance between
the strains, including alpha-haemolysin (Hla), col-
lagen adhesin (Cna), staphylokinase (Sak), coagulase
(Coa), lipase (Lip), enterotoxin C3 (Sec3), enterotoxin
Q (Seq), V8 protease (SspA) and cysteine protease
(SspB). Mice infected with MW2 or LAC produced
antibodies speciﬁc for known or putative virulence
factors, such as autolysin (Atl), Cna, Ear, ferritin (Ftn),
Lip, 1-phosphatidylinositol phosphodiesterase (Plc),
Sak, Sec3 and SspB, indicating the exoproteins are
made during infection in vivo. We used confocal
microscopy to demonstrate aureolysin (Aur), Hla,
SspA and SspB are produced following phagocytosis
by human neutrophils, thereby linking exoprotein
production in vitro with that during host–pathogen
interaction. We conclude that the exoproteins identi-
ﬁed herein likely account in part for the success of
CA-MRSA as a human pathogen.
Introduction
Staphylococcus aureus causes a wide range of human
diseases, including impetigo, cellulitis, food poisoning,
toxic–shock syndrome, necrotizing pneumonia,
endocarditis and sepsis (Lowy, 1998; Diekema et al.,
2001). Decades of selective pressure with b-lactam anti-
biotics and close proximity of susceptible hosts have
resulted in a high prevalence of methicillin-resistant
S. aureus (MRSA) in hospitals worldwide (Chambers,
2001; Diekema et al., 2001). Although these factors logi-
cally explain the high incidence of hospital-associated
MRSA infections, the molecular basis for the increased
incidence and severity of community-acquired (or associ-
ated) MRSA (CA-MRSA) infections among healthy indi-
viduals remains incompletely deﬁned (Chambers, 2001;
2005; McDougal et al., 2003; Fridkin et al., 2005; Miller
et al., 2005; Zetola et al., 2005). Recent studies indicate
strains that are the leading causes of CA-MRSA disease
in the United States, represented by pulsed-ﬁeld gel elec-
trophoresis (PFGE) types USA300-0114 (McDougal et al.,
2003; Fridkin et al., 2005; Kazakova et al., 2005; Diep
et al., 2006) and USA400 (Centers for Disease Control
and Prevention, 1999; Baba et al., 2002; McDougal et al.,
2003; Adem et al., 2005), have enhanced virulence com-
pared with leading causes of hospital infections (e.g.
USA200) (Voyich et al., 2005). In addition to their distinct
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CA-MRSA strains can be distinguished from one another
and from other S. aureus strains on the basis of multilocus
sequence typing (MLST or ST) and sequencing of the
variable number tandem repeats in the staphylococcal
protein A gene (spa); USA300-0114 is spa-type 1
(Shopsin et al., 1999) and multilocus sequence type ST8,
while USA400 is ST1 (Enright et al., 2000). Both strains
also have the type IV staphylococcal chromosomal cas-
sette mec element, which is common among CA-MRSA
but not typically found in hospital adapted nosocomial
MRSA (Baba et al., 2002; Voyich et al., 2005; Diep et al.,
2006). In addition, each strain has one or more common
names, such as Los Angeles County clone (LAC) or
FPR3757 (sequenced strain) used for USA300-0114
(Voyich et al., 2005; Diep et al., 2006), and MW2 for the
prototype USA400 strain (Centers for Disease Control
and Prevention, 1999; Baba et al., 2002). Enhanced viru-
lence of USA300-0114 (referred to herein as either LAC or
USA300) and USA400 (referred to herein as MW2) is
linked in part to their ability to circumvent killing by neu-
trophils and cause host cell lysis (Voyich et al., 2005). It is
likely that exoproteins (cell surface-associated and freely
secreted proteins) produced by these strains are an
important component of this enhanced virulence (Foster,
2005; Voyich et al., 2005; Diep et al., 2006).
Secreted virulence proteins of S. aureus can be catego-
rized based on proven or putative function. Cytolytic
toxins, such as haemolysins (Hla, Hlb, HlgABC) and leu-
kocidins (LukD/E and Panton–Valentine leukocidin, PVL),
oligomerize to form pores on the cell surface (Walev et al.,
1993; Bhakdi et al., 1998). Destruction of leucocytes
(especially neutrophils), which can be mediated by these
toxins, is likely a key component of CA-MRSA
pathogenesis. For example, PVL has high speciﬁcity for
granulocytes and is linked by epidemiology to CA-MRSA
disease (Lina et al., 1999), although our recent studies
indicate the toxin has a limited role in virulence (Voyich
et al., 2006). Staphylococcal enterotoxins are secreted
superantigens (SAg) that bind to major histocompatibility
complex (MHC) class II proteins, resulting in CD4+ T-cell
activation and immune modulation (Malchiodi et al., 1995;
McCormick et al., 2001; Orwin et al., 2002; Llewelyn
et al., 2004). S. aureus also secretes numerous pro-
teases and lipases that degrade host components, and
proteins that sequester antibody or inactivate antibiotics
(Foster, 2005). As a step towards understanding the role
played by S. aureus exoproteins in virulence, previous
proteomics-based studies identiﬁed immunogenic pro-
teins produced by strain COL (Vytvytska et al., 2002),
evaluated the role played by S. aureus agr and sigB on
secretion of virulence factors (Ziebandt et al., 2001), and
tested the effects of linezolid on production of virulence
factors (Bernardo et al., 2004). However, a comprehen-
sive analysis of the exoproteins produced by CA-MRSA
has not been conducted.
To that end, we used a proteomic approach to identify
exoproteins of LAC and MW2 during growth in vitro and
evaluated immunogenicity of the proteins using sera from
mice infected with each strain. In addition, we used con-
focal microscopy to determine that selected exoproteins
were produced within phagocytic vacuoles of human neu-
trophils following uptake, a phenomenon accompanied by
host cell lysis.
Results
Resolution and identiﬁcation of culture supernatant
proteins produced by CA-MRSA strains
As an initial step towards gaining a comprehensive under-
standing of exoproteins made by the most prominent
CA-MRSA strains, we resolved/identiﬁed proteins in MW2
(USA400) and LAC (USA300) culture supernatants using
2-dimensional gel electrophoresis (2-DGE) coupled with
automated direct infusion-tandem mass spectrometry
(ADI-MS/MS). Three hundred and ﬁfty-three and 270
protein spots were resolved from MW2 and LAC culture
media, respectively, at mid-exponential phase of growth
(Fig. 1A–D). By comparison, 625 MW2 and 581 LAC pro-
teins were resolved from culture supernatants at station-
ary phase of growth (Fig. 1B). Of the resolved exoproteins,
153 (60.2  18%) from cultures at mid-exponential growth
and 436 (67.9  6.6%) from cultures at stationary growth
matched between strains, indicating MW2 and LAC
produce numerous proteins that co-migrate during 2-DGE
(Fig. 2). We note that this analysis fails to account for
variations of same or similar proteins with slightly different
migration by 2-DGE.Therefore, our estimate of the degree
of similarity between the two strains at the level of exopro-
tein (60% to 68%) is relatively conservative.
Using ADI-MS/MS and excluding protein isoforms and
identiﬁcations from multiple gels, we identiﬁed 250 unique
proteins from MW2 and LAC culture supernatants at the
two phases of growth combined (98 at mid-exponential
phase of growth and 228 at stationary phase) (Fig. 2 and
Table 1). Proteins were separated into categories based
on functional annotation to facilitate subsequent analyses
(Fig. 1B and C, and Table 1).
Identiﬁcation of CA-MRSA exoproteins associated with
virulence
Twenty exoproteins (20%) identiﬁed at mid-exponential
growth and 33 (15%) of those at early stationary phase
of growth are known to be associated with virulence
(Fig. 1 and Table 1). There were essentially three sub-
categories of virulence determinants found in culture
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(PepS), aureolysin (Aur), staphylokinase (Sak), V8 pro-
tease (SspA), cysteine protease (SspB), serine protease
(SplC), lipase (Lip) and Xaa-Pro dipeptidase, were pro-
duced by each strain at either phase of growth (Fig. 1
and Table 1). These enzymes degrade and/or modify
proteins and lipids present in the growth environment
(McGavin et al., 1997; Karlsson et al., 2001; Massimi
et al., 2002; Imamura et al., 2005). For example, cys-
teine protease/staphopain B (SspB), which directly
cleaves kininogen, also works in concert with staphopain
A (ScpA) to promote vascular leakage and lower blood
pressure, thereby facilitating septic shock (Massimi
et al., 2002; Imamura et al., 2005). SspA causes release
of cell surface ﬁbronectin-binding protein (FnbB) and
immunoglobulin G (IgG)-binding protein A (protein A,
Fig. 1. Distribution and function of proteins found in MW2 and LAC culture supernatants.
A. MW2 and LAC were cultured to mid-exponential (Mid-exp.) or stationary phases of growth as indicated, at which point proteins were
identiﬁed/resolved using proteomics as described in Experimental procedures.
B. Numbers in yellow-shaded regions represent proteins identiﬁed in both MW2 and LAC supernatants at the indicated growth phase.
Numbers in red- or blue-shaded regions indicate proteins identiﬁed in MW2 or LAC supernatants respectively. Results are derived from three
separate experiments.
C. Proteins identiﬁed by ADI-MS/MS were categorized based upon functional annotation. Numbers are the per cent of total proteins identiﬁed.
D. Proteins identiﬁed at mid-exponential and stationary phases of growth were enumerated and categorized by functional annotation. Carb.
Met., carbohydrate transport and metabolism; AA Met., amino acid transport and metabolism; Vir. & Def., virulence and defence mechanisms;
Toxins & Hem., toxins and haemolysins; Stress Resp., stress response; Cell Div., cell division and maintenance; Prot. Synth., protein
synthesis; Nuc. Biosynth., nucleotide biosynthesis; FA Biosynth., fatty acid biosynthesis; Trans. & Rep., transcription and replication.
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increasing free FnbB and Spa (McGavin et al., 1997;
Karlsson et al., 2001).
A second group of molecules identiﬁed in CA-MRSA
culture media were those involved in bacteria–host inter-
action or adhesion, such as coagulase (Coa), collagen
adhesin (Cna), enolase (Eno), ﬁbrinogen-binding protein,
FnbA, FnbB, 1-phosphatidylinositol phosphodiesterase
(Plc), Spa and IgG-binding protein (Sbi) (Figs 1 and 2,
and Table 1). These molecules can activate the clotting
cascade (Coa) (Panizzi et al., 2006), mediate binding to
host tissues (Cna, Eno, FnbA and FnbB) (Patti et al.,
1992; Greene et al., 1995; Carneiro et al., 2004),
and sequester host antibody (Spa and Sbi) (Forsgren and
Sjoquist, 1966; Zhang et al., 1998). Although the function
of S. aureus Plc is uncharacterized, that of Listeria mono-
cytogenes promotes adhesion to epithelial cells and medi-
ates escape of the pathogen from phagosomes
(Krawczyk-Balska and Bielecki, 2005; Wei et al., 2005).
The toxins and haemolysins, namely alpha-haemolysin
(Hla), enterotoxin C3 (Sec3), enterotoxin H (Seh), entero-
toxin K (Sek), enterotoxin L (Sel2) and enterotoxin Q
(Seq), comprised at most 4% of the exoproteins produced
by MW2 and/or LAC in mid-exponential or early stationary
phases of growth (4/98 at mid-exponential phase and
6/229 at early stationary phase of growth respectively)
(Fig. 1 and Table 1). Unexpectedly, we failed to detect
gamma-haemolysin subunits (HlgA, HlgB and HlgC),
LukD/E, LukM, or either component of PVL (LukS-PV and
LukF-PV) in culture supernatants under the two growth
conditions tested.
Proteins involved in metabolism, biosynthesis,
transcription and replication are present in MW2 and
LAC culture supernatants
CA-MRSA culture supernatants contained 73 proteins
known to be involved in the transport and utilization of
carbohydrates or amino acids for energy (Table 1).
Thirty-ﬁve proteins known to participate in biosynthesis
of nucleotides, proteins and fatty acids, and 51
proteins involved in cell division, transcription and
replication, were also identiﬁed in culture media (Fig. 1
and Table 1). The observation that cytoplasmic
proteins were found in culture supernatant is not
unexpected, as numerous cycles of autolysis would
have occurred thereby releasing proteins into culture
medium (Lei et al., 2000; Chaussee et al., 2001; Trost
et al., 2005).
Stress response proteins are present in culture
supernatants
Twenty proteins associated with the response to envi-
ronmental stress were identiﬁed in MW2 and LAC
culture supernatants (Fig. 1 and Table 1). For example,
alkyl hydroperoxide reductase (AhpC and AhpF),
catalase (KatA), superoxide dismutase (SodA), thiore-
doxin (TrxA) and thioredoxin reductase (TrxB),
proteins that function to inactivate reactive oxygen
species, and heat shock proteins, GroES and DnaK,
were identiﬁed in culture supernatants at both phases
of growth (Fig. 1 and Table 1). Consistent with this
Fig. 2. 2-DGE analyses of culture supernatant proteins produced by MW2 and LAC. Proteins from MW2 (green) and LAC (magenta) culture
supernatants were analysed by proteomics. Left panel, proteins from cultures at mid-exponential (Mid-exp.) phase of growth. Right panel,
proteins from cultures at stationary (Stat.) phase of growth. White areas are regions of overlap. Selected proteins are indicated. Images are
representative of three separate experiments.
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Protein name (Entrez protein name)
a
Entrez
protein
a MW
E pI
E MP SC%
MS/MS
MOWSE
score
Carbohydrate transport and metabolism (61)
Acetate kinase (AckA)
C1,D1 13701506 44029 5.7 10 31 226
Acetoin reductase (ButA)
D2 49482369 27199 5.0 3 15 104
Aconitate hydratase (AcnA)
B1,C1,D1 49241672 98850 4.9 24 34 878
Adenylate kinase (Adk)
B1,D2 49484445 23959 4.8 6 29 245
Adenylosuccinate synthetase, putative (PurA)
C1 49482270 47522 5.1 4 12 146
Alcohol dehydrogenase (Adh)
B5,D6 14246373 36039 5.5 13 45 558
Alcohol dehydrogenase, zinc-containing (AdhE)
D1 87162223 36244 5.3 4 13 93
Aldehyde dehydrogenase (AldA1)
B1,D1 49242475 51936 5.1 7 19 179
ATP synthase beta chain (AtpD)
A1,C2,D1 49484327 51368 4.7 4 11 101
ATP synthase alpha chain (AtpA)
D1 49484329 54550 4.9 4 9 82
Citrate synthase II (GltA)
B2,C1,D2 49483937 42566 5.4 14 50 507
CoA synthetase protein, putative (FadE)
B1,C1,D1 49483408 42060 4.9 9 23 256
Deoxyribose-phosphate aldolase (Dra)
B1 14247910 23327 4.7 3 17 56
Dihydrolipoamide acetyltransferase: subunit E2 (PdhC)
A2,C2,D2 581570 46411 4.9 16 46 817
Dihydrolipoamide dehydrogenase: subunit E3 (PdhC)
A2,B2,C1,D2 48874 49421 5.0 16 46 803
Phosphoglycerate mutase (Gpm)
B2 14246544 56419 4.7 12 29 590
Enolase (Eno)
A2,B3,C2,D4 6015099 47088 4.5 18 54 1257
Methylenetetrahydrofolate dehydrogenase (FolD)
B2,D1 49244345 30824 5.4 13 68 859
Formate tetrahydrofolate ligase (Fhs)
B1,C1,D1 83288210 59876 5.8 16 44 759
Formate acetyltransferase (PﬂB)
D2 49482458 84808 5.3 6 11 193
Fructose bisphosphate aldolase class I (Fba)
A1,B4,C2,D6 88196553 33034 4.9 14 57 683
D-Fructose 6-phosphate amidotransferase (GlmS)
D1 49484376 65839 4.9 6 15 151
6-Phospho-beta-galactosidase (LacG)
A1 644835 116131 5.3 1 1 42
Glucose 6-phosphate isomerase A (GpiA)
A1,B1,C1,D1 49244181 49777 4.8 20 53 1008
Glucose 6-phosphate 1-dehydrogenase (Zwf)
D1 49483755 56929 5.3 7 15 227
Glyceraldehyde 3-phosphate dehydrogenase 1 (Gap)
A2,B5,C3,D5 49244087 36258 4.9 13 47 770
Glyceraldehyde 3-phosphate dehydrogenase subunit B (GapB)
D1 38195941 36899 6.0 4 14 106
Glyceraldehyde 3-phosphate dehydrogenase subunit C (GapC)
C1,D1 38195943 36227 4.9 3 10 65
Glycerate dehydrogenase (MW2224)
B1,D2 14248079 34681 5.1 10 41 377
Glycine cleavage system H protein (GcvH)
A1,C1,D2 49241194 14072 4.0 2 30 194
Glycine C-acetyltransferase, similar to (MW0505)
D1 14246318 41426 5.3 2 5 58
Hexulose 6-phosphate synthase, putative (SgaH)
B1,D1 87160968 22404 4.6 12 81 656
Hydrolase (HAD superfamily) (MW0575)
B1,D1 49241218 27962 4.5 4 16 67
Indole-3-pyruvate decarboxylase, putative (IpdC)
D1 14245955 60490 5.1 1 2 59
Isocitrate dehydrogenase (Idh)
B1,D1 49244963 46408 4.9 4 10 129
L-Lactate dehydrogenase 1 (Ddh)
B3,D4 57286685 34562 5.0 10 34 368
Malate:quinone oxidoreductase (Mqo2)
A1,B1,C1,D1 21205698 55892 6.2 7 17 301
Mannitol-1-phosphate 5-dehydrogenase (MtlD)
B3,D1 49242510 40801 5.0 10 36 357
2-C-Methyl-D-erythritol 4-phosphate cytidylyltransferase (IspDF)
B1 49482491 26640 5.4 3 12 77
NAD-dependent dehydrogenase, putative (MW2068)
B2 49245380 24057 5.0 15 81 643
Oxoglutarate dehydrogenase (Ogdh)
B1,D1 21204471 105289 5.4 14 22 401
Phosphate acetyltransferase, putative (Pta)
A1,B4,C1,D5 22212856 20383 4.8 8 44 523
Phosphoenolpyruvate carboxykinase (PckA)
B1,D1 49484033 59370 5.7 20 44 678
Phosphogluconate dehydrogenase (Pgd)
A1,C1,D1 14247282 51751 5.1 5 15 122
Phosphopentomutase, putative (Drm)
A1,B1,C2,D2 14246544 56419 4.7 14 36 672
Phosphoenolpyruvate-protein phosphatase (PtsI)
B1,D1 1070386 63179 4.7 12 22 490
6-Phosphofructokinase (PfkA)
B2,D1 49244967 34818 5.6 11 34 327
6-Phosphogluconate dehydrogenase, decarboxylating (Gnd)
B1,D2 49483761 51770 5.0 12 30 564
Phosphoglycerate kinase (Pgk)
A1,B2,C3,D2 49483031 42575 5.2 14 47 615
1-Pyrroline-5-carboxylate dehydrogenase (RocA)
B1,D1 21205647 56833 5.0 16 39 687
Pyruvate carboxylase, putative (PycA)
B1,D1 49483277 128451 5.2 14 14 353
Pyruvate dehydrogenase E1 component, alpha subunit, putative (PdhA)
A1,C2 49244374 41357 4.9 7 32 239
Pyruvate dehydrogenase E1 component, beta subunit, putative (PdhB)
A2,B4,C1,D3 57285889 35194 4.7 10 43 525
Pyruvate kinase (Pyk)
A1,B2,C3,D1 49242068 63103 5.2 18 38 610
Short chain dehydrogenase MW2249 (MW2249)
D3 21205420 31769 4.6 4 12 179
Succinyl-CoA synthetase (SucD)
B1 49244528 31506 5.5 5 25 154
Succinyl-CoA synthetase (SucB)
D3 49483408 42060 4.9 7 18 246
Tagatose-bisphosphate aldolase, putative (LacD1)
A1,B6 49245361 30817 5.0 8 40 371
Transaldolase, putative (MW1721)
B4,D2 14247553 25742 4.8 7 37 273
Transketolase (Tkt)
B1,D1 57284532 72206 5.0 19 35 703
Triosephosphate isomerase (Tpi)
A1,B3,C2,D3 49483032 27245 4.8 8 39 477
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Protein name (Entrez protein name)
a
Entrez
protein
a MW
E pI
E MP SC%
MS/MS
MOWSE
score
Amino acid transport and metabolism (12)
Alanine dehydrogenase 2 (Ald2)
D1 49244722 40209 5.2 6 18 173
Amidophosphoribosyltransferase precursor, putative (PurF)
B1 49244352 54363 6.1 12 23 426
Cysteine synthase (CysK)
C2 82750220 32969 5.4 8 52 273
3-Deoxy-7-phosphoheptulonate synthase (MW1680)
B1,D1 49483977 40609 5.8 7 24 229
Glucosamine-fructose 6-phosphate aminotransferase (GlmS)
D1 14247927 65795 4.9 5 11 110
Glutamine synthetase (GlnA)
B1 1134886 50808 5.1 11 34 400
Imidazolonepropionase (HutI)
D1 87162411 45011 5.2 5 15 101
Phosphoribosylformylglycinamidine synthase I (PurQ)
B1 14246838 24541 5.0 3 21 108
Phosphotransferase system enzyme IIA-like protein (SH1484)
D1 88195154 17949 4.5 4 33 144
SNO glutamine amidotransferase family protein (MW0475)
D1 49482749 20617 5.7 6 43 211
Thiamine pyrophosphate enzyme, putative (MW0162)
B1,D1 49240559 60503 5.0 6 13 181
Urocanate hydratase (HutU)
C1 14248105 60626 5.2 4 12 55
Virulence/defence mechanisms (31)
Aminopeptidase PepS (PepS)
D1,S 87161826 46805 4.8 8 19 226
Aureolysin (Aur)
C1,D1,S 6119705 56281 5.1 3 8 102
Chitinase (MW0945)
D1,S 49483226 11338 6.6 2 32 75
Coagulase (Coa)
A4,C7,D1,S 46540 71675 8.4 20 37 920
Collagen adhesin precursor (Cna)
A2,B1,L,M,S 21205785 132921 5.9 7 7 199
Ear (Ear)
B1,D1,M,S 21203924 20322 8.6 4 19 115
Esterase\lipase (MW2501)
B1,D2,S 14248355 30986 4.7 10 52 415
Fibrinogen-binding protein-related (MW1037)
A1,C1,S 49244435 12171 10.4 3 27 115
FmtB protein (FmtB)
A1,D1 14247939 263611 4.6 9 4 229
Fibronectin-binding protein A (FnbA)
C3,L,M,S 87161146 111642 4.6 9 13 254
Fibronectin-binding protein B (FnbB)
A1,B2,C2,L,M,S 87162339 103492 4.7 9 12 265
IgG-binding protein (Sbi)
A2,S 49245643 50099 9.4 11 26 330
IgG-binding protein A precursor (Spa)
A9,C7,D4,L,M,S 83682325 49338 5.7 16 45 666
Lipase (Lip)
C3,D8,S 1095875 76845 7.1 19 30 947
Lysophospholipase, putative (MW1732)
D1,S 87162009 31019 5.1 9 53 306
Metallo-beta-lactamase superfamily protein (YycJ)
B1,S 49483948 25306 5.0 4 24 101
Mrp protein (Mrp)
C1 5834649 262876 4.6 9 4 250
1-Phosphatidylinositol phosphodiesterase (Plc)
B1,D3,S 1172527 35213 6.5 13 52 452
Putative sulfatase (MW0681)
B1,C1,D2,M,S 49244034 74353 9.0 8 17 349
SspA, V8 protease (SspA)
B2,D4,S 12025238 36304 5.0 6 27 337
SspB, cysteine protease precursor (SspB)
A1,B3,C2,D9,S 12025239 44491 5.7 15 44 738
Serine protease SplC (SplC)
B1,D2,S 88195634 26082 6.3 7 27 212
Staphylokinase precursor (Sak)
B4,C1,D6,S 21205055 18483 6.8 7 67 411
Succinyl-diaminopimelate desuccinylase (MW1943)
B1 13701801 45109 4.6 6 16 158
Tetracycline resistance protein (TetP)
B1,M,S 6094458 72677 5.3 1 2 60
ThiJ/PfpI family protein, protease 1 (MW1815)
B3,D2 49240910 32171 5.0 6 67 323
Trigger factor (prolyl isomerase) (Tig)
A2,B3,C2,D2 49483918 48565 4.3 8 24 439
Tripeptidase, similar to (MW1465)
B1 14247283 40172 5.0 4 12 88
Truncated MHC class II analogue protein (SAOUHSC 02466)
D4 88196118 15438 8.7 7 55 300
Xaa-His dipeptidase (MW1694)
B2,C1,D1,S 49245019 52775 4.6 13 34 535
Xaa-Pro dipeptidase (MW1482)
B1,D3,S 49483779 39357 5.2 9 32 314
Toxins and haemolysins (7)
Alpha-haemolysin, chain G (Hla)
C3,D4,S 2914575 33227 7.9 14 51 666
Enterotoxin C3 (Sec3)
B4,S 295149 27634 7.2 17 58 799
Enterotoxin H (Seh)
B4,S 9955226 25128 5.2 7 38 282
Enterotoxin K (Sek)
C1,D2,S 87161791 27733 8.3 6 25 252
Enterotoxin L, extracellular (Sel2)
D2,S 14247781 27479 9.0 2 4 83
Enterotoxin Q (Seq)
B2,C2,D2,S 87161054 28129 7.7 8 43 358
Exotoxin (SAUSA300_0407)
C1,S 88194194 25350 8.5 2 15 96
Stress response proteins (20)
Alkaline shock protein 23 (Asp23)
A1,B7,C5,D11 49484402 19180 5.1 8 60 301
Alkyl hydroperoxide reductase subunit C (AhpC)
A1,B2,C2,D4 49482631 20963 4.9 7 53 514
Alkyl hydroperoxide reductase subunit F (AhpF)
B1,D1 14246148 54674 4.7 5 11 164
ATP-dependent Clp proteinase chain (ClpP)
B2,D3,M 14248322 77810 4.8 25 49 1416
Catalase (KatA)
B1,C1,D2 7161887 58287 5.3 15 31 680
Chaperone protein DnaK, HSP70 (DnaK)
A2,B1,C2,D,M 1169381 66307 4.6 15 34 875
Chaperone protein HchA, Hsp31 (HchA)
B1 49240910 32171 5.0 4 14 147
Cold shock protein (CspA)
B2,C2,D2 49483592 7317 4.5 3 78 188
General stress protein 26 (MW2302)
B1,D1 49245607 15807 5.1 4 40 199
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GroES (GroES)
D1 18028156 10453 5.1 2 26 68
NAD(P)H-ﬂavin oxidoreductase, similar to (Frp)
D1 14248297 25359 5.5 4 17 56
Nitric oxide dioxygenase (MW0216)
D1 14246007 42932 5.2 4 12 104
OsmC-like protein (MW0781)
B3,D1 49244117 15320 4.8 3 25 113
Peroxiredoxin reductase (AhpF)
D1 49243746 11325 6.4 3 42 67
SrrA (SrrA)
D1 37781574 28143 5.2 6 30 288
Superoxide dismutase (SodA)
A1,B2,C1,D2 49483802 22697 5.1 6 45 303
Thioredoxin (TrxA)
B1,D2 49483308 11433 4.4 5 56 223
Thioredoxin (MW1870)
B1,D1 49484170 21902 5.2 7 37 259
Thioredoxin reductase (TrxB)
B1,C1,D2 32468851 33595 5.2 9 30 456
Universal stress protein, putative (MW1653)
B1,D5 49483951 18463 5.6 8 63 497
Cell division and maintenance (33)
Aminoglycoside phosphotransferase (AphA)
C1 11991167 30624 4.5 3 16 64
Autoinducer-2 production protein (LuxS)
D1 49484358 17502 5.4 4 23 140
Autolysin (Atl)
A2,B1,C3,D4,S 14248419 69186 6.0 20 43 867
Cyclophilin type peptidyl-prolyl cis-trans isomerase, putative (MW0836)
D1 49483114 21605 4.6 4 18 108
Cell division initiation protein DivIVA (MW1335)
B1,D1 49483601 29963 4.4 3 11 114
Cell division protein FtsZ (FtsZ)
A1,B1,D2 38604824 41413 5.0 5 15 167
Cytosol aminopeptidase family protein (PepA)
D1 49483102 54140 5.7 9 23 215
GAF domain protein (MW1661)
D1 88195528 17100 4.9 3 22 93
HMG-CoA synthase (MvaS)
B3,D1 9937361 43191 5.0 10 31 414
Histidine-containing phosphocarrier protein (PtsH)
D2 46908 9505 4.4 2 27 109
Ferritin (Ftn)
B3,D7 49242263 19590 4.7 6 31 450
Putative non-haem iron-containing ferritin (MW2063)
D2 49484363 16681 4.6 2 19 120
Formylmethionine deformylase homologue (Def)
D1 14246861 20546 5.8 6 38 111
Fumarylacetoacetate (FAA) hydrolase family protein (Faa)
B1 49244187 33093 4.8 3 13 72
Methionine aminopeptidase (Map)
D1 49484129 27485 5.2 3 14 105
Malonyl CoA-acyl carrier protein transacylase (FabD)
D1 14247000 33628 4.9 5 23 109
Manganese-dependent inorganic pyrophosphatase (PpaC)
A1,C1,D1 492245182 34279 4.7 6 23 199
Monofunctional biosynthetic peptidoglycan transglycosylate (MW1814)
D1 49483860 11941 3.9 2 10 84
Naphthoate synthase (MenB)
D1 14246815 30392 5.4 6 18 162
Peptidoglycan hydrolase (LytM)
C2,S 2239274 35147 6.1 4 20 207
Putative 3-methyl-2-oxobutanoate hydroxymethyltransferase (PanB)
D1 49245819 29237 5.6 8 30 348
Secretory antigen precursor SsaA (SsaA)
D1 87159889 17388 5.8 1 9 73
Stage V sporulation protein (SpoVG)
B1 13700388 12312 4.9 3 33 62
tRNA, Arginyl-tRNA synthetase (ArgS)
B1,D1 49240966 62312 5.1 7 16 220
tRNA, Aspartyl-tRNA synthetase (AspS)
D1 49483875 66527 5.0 10 17 163
tRNA, Cysteinyl-tRNA synthetase (CysS)
D1 46395518 53651 5.3 9 23 280
tRNA, Glutamyl-tRNA amidotransferase subunit B (GatB)
C1,D3 82751553 53607 5.1 9 24 229
tRNA, Glycyl-tRNA synthetase (GlyS)
D1 49483813 53586 5.0 4 8 107
tRNA, Isoleucyl-tRNA synthetase (IleS)
D1 49244476 104825 5.3 8 10 179
tRNA, Leucyl-tRNA synthetase (LeuS)
B1,D1 21204871 91926 5.0 9 17 343
tRNA, Phenylalanyl-tRNA synthetase beta subunit (PheT)
C1,D1 14246909 88885 4.7 9 13 317
tRNA, Seryl-trna synthetase (SerS)
B1,D1 14245776 48609 5.0 10 27 327
tRNA, Threonyl-tRNA synthetase 1 (ThrS)
C1,D1 14247455 74341 5.3 11 20 281
Protein synthesis (18)
Acetyltransferase (GNAT) family protein (MW2324)
D2 49483339 16991 4.9 5 32 174
Aminotransferase, putative (RocD)
B1,C1 492241363 54376 6.1 7 19 229
Branched-chain amino acid aminotransferase (IlvE)
D1 82750262 40061 5.0 5 20 220
Deblocking aminopeptidase, similar to (MW1253)
D1 49483560 37848 5.3 1 3 58
Formiminoglutamase (HutG)
D1 87160628 34491 5.4 6 29 223
Glutamine ammonia ligase (GlnA)
A1,C1,D1 14247080 50822 5.1 9 34 314
30S Ribosomal protein S1 (RpsA)
A1,B1,C1,D2 14247247 43283 4.6 15 51 740
30S Ribosomal protein S2 (RspB)
B2,C1,D1 57286011 29377 5.3 7 26 306
30S Ribosomal protein S6 (RpsF)
A1,B2,C2,D3 49482595 11588 5.1 6 58 268
S30EA Family ribosomal protein, putative (MW0714)
B1,D2 49244067 22199 5.2 5 31 211
50S Ribosomal protein L7/L12 (RplL)
A2,B2,C2,D4 88194302 12704 4.6 7 72 352
50S Ribosomal protein L10 (RplJ)
B1,C1,D1 49243847 17672 4.8 5 51 242
50S Ribosomal protein L25 (RplY)
C1 49243808 23773 4.4 4 23 74
O-acetylserine (thiol)-lyase, putative, cysteine synthase (CysK)
B2,C1,D2 49243820 32955 5.4 11 58 500
Ornithine aminotransferase (RocD1)
B1,D3 49483117 43444 5.4 11 31 543
Secretory antigen precursor (SsaA)
C3 49242648 16997 5.8 1 9 86
Secretory antigen precursor SsaA (MW0627)
C1 49243980 28155 6.1 3 14 69
Serine hydroxymethyltransferase (GlyA)
B1,D1 49245349 45144 5.8 10 29 422
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Nucleotide biosynthesis (16)
Adenylosuccinate lyase (PurB)
D1 49484149 49572 5.6 7 18 154
Adenylosuccinate synthase (PurA)
B1,D2 49482270 47522 5.1 5 14 217
Amidophosphoribosyltransferase precursor (PurF)
B1,D2 49244352 54363 6.1 12 23 426
Carbamoyl-phosphate synthase large chain (CarB)
C1 14246973 117098 4.9 3 3 54
GMP synthase (GuaA)
D2 38372353 58149 4.9 6 13 200
Inositol-monophosphate dehydrogenase (GuaB)
A1,B1,C1,D1 21203531 52790 5.6 10 35 338
Phosphoribosylamine-glycine ligase (PurD)
D1 14246844 41946 5.0 2 6 50
Phosphoribosylaminoimidazole-succinocarboxamide synthase (PurC)
B1,D1 88194764 26676 5.3 12 62 494
Phosphoribosylformylglycinamidine cyclo-ligase (PurM)
D2 14246841 36966 4.8 7 26 252
Phosphoribosylformylglycinamidine synthetase (PurL)
B1,D1 14246839 79513 4.8 10 16 245
Phosphoribosylformylglycinamidine synthase (PurS)
D2 14246838 24541 5.0 7 43 215
Phosphoribosylformylglycinamidine synthase, PurS component (MW0950)
B2 49241360 9929 4.7 4 68 225
Polyribonucleotide nucleotidyltransferase (PnpA)
B1,D1 49244556 77342 4.9 14 23 530
Purine nucleoside phosphorylase (DeoD1)
A1,B3,D2 49484362 25892 4.9 6 35 329
Pyridoxine biosynthesis protein (MW0474)
A1,C1,D1 49482748 31972 5.1 8 31 267
Uracil phosphoribosyltransferase (Upp)
D1 49484336 23035 6.1 9 58 496
Fatty Acid Biosynthesis (1)
Trans-2-enoyl-ACP reductase (FabI)
B1,D1 56001093 24601 5.2 7 53 226
Transcription and Replication (18)
2′-5′ RNA ligase (MW0896)
B1,D1 49244233 19315 4.9 6 40 201
Accessory gene regulator A (AgrA)
D1 14247812 27903 5.9 5 18 92
DNA-directed RNA polymerase alpha chain (RpoA)
C2 49484440 34990 4.7 9 40 292
DNA polymerase III, beta chain (DnaN)
C1,D1 49482255 41888 4.7 8 25 194
DNA-directed RNA polymerase delta subunit (RpoE)
C1 49245364 20868 3.6 2 14 84
Translation elongation factor G (Fus)
A2,B2,C3,D2 49243855 76564 4.8 19 40 915
Elongation factor TS (Tsf)
A2,B3,C3,D5 14247027 32473 5.2 15 57 683
Elongation factor P, putative (Efp)
D1 49483778 20541 4.8 2 11 82
RsbW (RsbW)
B1 37781578 17896 4.7 3 20 70
TatD related Dnase, putative (MW0446)
D1 49482718 29263 5.1 4 17 126
Transcription pleiotropic repressor (CodY)
B1,D2 49483418 28737 5.9 8 35 354
Transcription termination-anti-termination factor (NusA)
C1,D1 14247036 43729 4.6 9 29 242
Transcriptional regulator (MW0363)
B2,D3 14246155 15127 5.0 7 65 301
Transcriptional regulator, LytR family (SAUSA300_0958)
D1 1723223 23880 5.7 5 33 170
Transcriptional regulator, LytR family (MW0939)
C1,B2 57284435 45657 6.0 6 20 144
Translation initiation factor IF-1 (InfA)
B1 49484444 8274 6.7 2 38 64
Translation elongation factor Tu (Tuf)
A2,B1,C2,D3 49243856 43077 4.7 16 59 871
Transposase (MW2398)
B2,D2 49484688 16446 5.6 4 33 191
Miscellaneous (13)
IIIG9 protein, similar to- (LOC576703)
B1 72179405 52711 9.4 1 2 51
6,7-Dimethyl-8-ribityllumazine synthase (RibH)
B1,D1 49242141 16412 5.7 7 73 342
ABC transporter-associated protein, SufB (MW0799)
D1 49483078 52512 5.1 7 18 139
Amylase (MalA)
D1 18145251 77435 5.9 1 1 54
Aldo/keto reductase family protein (MW2127)
D1 49482959 32339 5.2 4 12 114
Arsenate reductase family protein (MW0785)
D1 49483064 13591 6.7 3 49 133
Lipoate synthase (LipA)*
A1 27807337 16468 6.3 2 17 54
Cell wall surface anchor family protein (MW2416)
C1,D1 57285190 136262 5.7 16 16 804
Short chain dehydrogenase (MW2249)
B1 14248102 31777 4.7 2 5 72
Immunodominant antigen A (IsaA)
A9,B5,C13,D2 14248343 24189 5.9 4 23 259
N-Acetylglucosamine 6-phosphate deacetylase (NagA)
D1 87161324 43089 5.4 7 20 123
4-Nitrophenylphosphatase-probable (MW0811)
B1 82750544 27962 4.5 4 16 61
SufD (SufD)
D1 82750525 48518 5.4 5 18 69
Unknown (20)
Conserved hypothetical protein (SAUSA300_0871)
D1 88194663 33093 4.8 9 42 262
Conserved hypothetical protein (SAUSA300_0916)
D1 88194708 19314 5.0 7 47 249
Conserved hypothetical protein (SAUSA300_1856)
D2 88195657 19536 6.1 7 46 247
Hypothetical exported protein (MW0347)
B6,D7 49243694 21261 5.7 3 14 115
Hypothetical exported protein (MW2606)
B1,D1 82752265 18700 4.7 3 25 147
Hypothetical cytosolic protein (MW0395)
C1,S 14246202 55465 5.1 14 32 487
Hypothetical protein (MW0542)
B1 14246355 29371 5.1 3 14 97
Hypothetical protein (MW0819)
B1,D1,M 49244219 69762 5.1 14 30 604
Hypothetical protein (MW2068)
D1,S 4126674 22954 5.2 10 62 369
Hypothetical protein (SAUSA300_0408)
A1,C5,S 57285506 56443 4.8 19 40 899
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in MW2 and LAC during phagocytosis by human neu-
trophils (Voyich et al., 2005). Further, heat shock pro-
teins such as DnaK and GroEL have been shown to be
immunogenic in patients with S. aureus endocarditis
(Qoronﬂeh et al., 1993; 1998), suggesting they are exo-
proteins in vivo.
MW2 and LAC produced numerous exoproteins of
unknown function
We identiﬁed 20 culture supernatant proteins with no
characterized function, including four putative exported
proteins (Fig. 1, Table 1 and Table S1) (Baba et al., 2002;
Diep et al., 2006). Fourteen of these proteins were con-
served across 10 sequenced strains of S. aureus
(Table S1). Genes encoding MW0395 and MW1757
reside within Type II genomic islands of MW2 known as
nSaa and nSab respectively, and each is located near or
among putative virulence determinants (Baba et al.,
2002). MW1884 is encoded by MW2 prophage FSa3 and
is juxtaposed to the gene encoding staphylokinase (sak),
a known virulence factor in S. aureus (Baba et al., 2002).
Several other exoproteins with no characterized function,
such as MW0542, MW1795, MW2068, SAUSA300_0871,
SAUSA300_0916 and SAUSA300_2327, have homology
to enzymes that participate in metabolism or replication,
or respond to stress (Table S1). It will be important to
determine whether some of these proteins have a role in
virulence and/or if they are potential vaccine targets.
Selected MW2 and LAC exoproteins differ in abundance
Although MW2 and LAC produced many common
exoproteins, 11 exoproteins detected at either phase
of growth differed in abundance between the strains
(Figs 3 and 4). Hla and a putative surface protein
(SAUSA300_0408) were in greater abundance in LAC
culture supernatants at mid-exponential growth phase,
and multiple repeat polypeptide (Mrp), Sak, and
Coa were found exclusively in the same supernatants
(Fig. 3A). By comparison, Cna, Sec3 and a putative
exported protein (MW0355) were identiﬁed as exopro-
teins only in MW2 culture supernatants at mid-exponential
growth (Fig. 3B).
At stationary phase of growth, Hla, Sak, Lip, Seq, SplC,
SspA, SspB and Sek were either increased  2-fold in
LAC supernatants or were found only in those superna-
tants (Fig. 3D). There was far more Cna (39.5-fold) in
MW2 supernatants at this phase of growth, and Sec3 and
MW0577, a protein of unknown function, were detected
only in MW2 culture media (Fig. 3E). Differences in exo-
proteins between these strains may underlie in part the
noted variances in disease phenotypes (Baba et al.,
2002; Kazakova et al., 2005; Miller et al., 2005; Voyich
et al., 2005; Diep et al., 2006).
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Hypothetical protein (SAUSA300_0279)**
D1,M,S 77383233 24390 6.9 1 5 51
Hypothetical protein (MW1884)
A1,M,S 30043928 13044 9.3 2 26 99
Hypothetical protein (MW0577)
B1,S 49482843 18554 9.2 4 25 124
Hypothetical cytosolic protein (MW1786)
B1,C1,D1 49484087 13302 4.4 9 85 406
Hypothetical protein (MW1795)
A2,B1,D2 49484096 22344 5.3 10 58 394
Hypothetical protein (MW2099)
B1,D1 49484393 10000 6.1 3 45 95
Hypothetical protein (SAUSA300 2327)
D1 87161861 15876 4.9 7 58 336
Hypothetical protein (SAUSA300 pUSA010004)
C1,M,S 87159841 21257 9.3 2 11 55
Putative exported protein (MW0355)
B8,M 49243745 56170 5.0 17 45 620
Putative exported protein (MW1757)
D2,S 49245076 20371 6.8 3 21 100
a. The Mascot search results displayed above (Entrez Protein number, MW, pI, MP, SC%, and MS/MS MOWSE score) are from the best protein
match to published S. aureus genomes. In many instances, database searches were performed before the genome sequence of USA300 was
published and the best match is to a protein from another published S. aureus strain. However, the Entrez Protein name indicates the name of the
likely MW2 or USA300 protein. SC, sequence coverage. MP, matched peptides.
AMW2 supernatants from mid-exponential phase of growth.
BMW2 supernatants from stationary phase of growth.
CLAC supernatants from mid-exponential phase of growth.
DLAC supernatants from stationary phase of growth.
ETheoretical or predicted.
LContains an LPXTG cell wall anchoring signal sequence.
MContains probable transmembrane regions.
SContains a probable N-terminal signal peptide sequence.
1-8Number after the letter
A,B,C or
D indicates number of times a protein was identiﬁed.
*Best Mascot search homology was to Cathelicidin 4 [indolicidin] [Bos taurus].
**Best Mascot search homology was to Pﬂ_3008 [Pseudomonas ﬂuorescens PfO-1] (ABA74746).
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culture supernatant proteins produced during
growth in vitro. Differential analysis of MW2
and LAC culture supernatant proteins was
performed as described under Experimental
procedures. Proteins more abundant in/found
only in LAC (A and D) or MW2 (B and E)
supernatants. Panels C and F represent
proteins equally abundant in MW2 and LAC.
The phase of growth at which the analysis
was performed is indicted to the left of the
panels. Results are the mean  SD of three
separate experiments at each phase of
growth.
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To reconcile exoproteins produced by MW2 and LAC in
vitro and those made during infection in vivo, we used a
mouse abscess model to generate immune/convalescent
sera from mice infected with MW2 and LAC (Voyich et al.,
2006). Following 2-DGE and transfer to nitrocellulose,
MW2 and LAC exoproteins were probed with convales-
cent serum from mice infected with either MW2 or LAC.
Several proteins from these CA-MRSA strains were com-
monly immunogenic in mice (Fig. 4). For example, AhpC,
Atl, formate tetrahydrofolate ligase (Fhs), glyceraldehyde
3-phosphate dehydrogenase (Gap), Lip and SspB were
immunogenic in mice infected with either strain (Fig. 4 and
Table 2). Cna, Sec3 and Sak are known virulence factors
that were immunogenic in mice infected with either MW2
(Cna and Sec3) or LAC (Sak) (Fig. 4 and Table 2), ﬁnd-
ings consistent with the differential analysis of exoproteins
produced in vitro (compare Figs 3 and 4). Although many
other immunogenic proteins were detected by our analy-
sis, many were cross-reactive with non-immune sera
(unboxed, unmarked protein spots, Fig. 4) or could not be
identiﬁed with absolute certainty (indicated by numbers,
Fig. 4). Taken together, these data provide strong support
to the idea that proven or putative virulence factors, such
as Atl, Cna, Lip, Sak, Sec3 and SspB, are made during
CA-MRSA infection in vivo.
Phagocytosis of CA-MRSA by human neutrophils
triggers production/secretion of virulence factors
To determine if production of selected exoproteins is trig-
gered by interaction of S. aureus with host cells and/or if
the proteins are made within phagosomes, we used con-
focal laser-scanning microscopy to evaluate production of
Aur, Hla, SspA and SspB after phagocytosis by human
polymorphonuclear leucocytes (PMNs) (Figs 5 and 6).
Notably, there was a time-dependent increase in Aur, Hla,
SspA and SspB produced by MW2 and/or LAC within
neutrophil phagocytic vacuoles (Figs 5 and 6, yellow
arrowheads). There was also redistribution of each mol-
ecule over time; at 15 or 60 min proteins were typically
localized only to S. aureus, whereas at 3 or 4 h after
phagocytosis each molecule was diffused within larger,
more mature phagosomes or distributed throughout the
cell (Figs 5 and 6, yellow arrowheads). Accumulation of
these molecules late during phagocytosis correlates well
with the noted PMN lysis caused by MW2 and LAC
(Figs 5 and 6) (Voyich et al., 2005). Production of viru-
lence factors within phagosomes is consistent with the
notion that these proteins are made during infection
in vivo.
Discussion
The striking increase in CA-MRSAinfections over the past
few years has prompted an intense search for the under-
lying molecular determinants. To date, few virulence
factors are associated speciﬁcally with CA-MRSAdisease
and no single determinant appears to account for the
increased incidence and severity of CA-MRSA infections
(Lina et al., 1999; Baba et al., 2002; de Bentzmann et al.,
2004; Diep et al., 2004; 2006; Fridkin et al., 2005; Voyich
et al., 2006). It is almost certain that a combination of
virulence determinants, including S. aureus exoproteins,
and host susceptibility promote disease in otherwise
healthy subjects. Inasmuch as exoproteins produced by
Fig. 4. Exoproteins produced by MW2 and
LAC during infection. Culture supernatant
proteins made by MW2 or LAC at the
indicated phase of growth were separated by
2-DGE, transferred to nitrocellulose
membranes, and probed with convalescent
sera from mice infected with each strain or
non-immune sera (not shown). Proteins
immunoreactive only with sera from infected
mice are indicated (boxed). Unidentiﬁed
immunoreactive proteins are annotated with
Arabic numbers. Immunoblots are
representative of three separate experiments.
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defence (Voyich et al., 2005) and thereby contribute to
disease, we performed a comprehensive analysis of exo-
proteins produced by MW2 and LAC in vitro and during
infection.
A limited number of proteomics-based studies have
investigated exoproteins of S. aureus, typically using
strain COL or laboratory-derived strains (Ziebandt et al.,
2001; 2004; Nakano et al., 2002). For example, Ziebrandt
et al. recently compared S. aureus strains RN6390 and
RN6911 and identiﬁed 43 exoproteins produced in vitro,
including many controlled by accessory gene regulator
(agr) and/or alternative sigma factor óB (sigB) (Ziebandt
et al., 2004). Nakano et al. identiﬁed 29 exoproteins pro-
duced by MRSA strains using 2-DGE coupled with
N-terminal peptide sequencing (Nakano et al., 2002). By
comparison, numerous studies have reported individual
S. aureus exoproteins that promote pathogenesis, includ-
ing proteases (McGavin et al., 1997; Karlsson et al.,
2001; Imamura et al., 2005), enterotoxins and exotoxins
(Dinges et al., 2000; McCormick et al., 2001), and leuko-
toxins and haemolysins (Kaneko and Kamio, 2004).
Table 2. Immunogenic (in vivo expressed) exoproteins of MW2 and LAC.
Protein
a MW2 LAC Immunoreactivity
AhpC, alkyl hydroperoxide reductase ME, S ME, S NI, I
AroA, chorismate mutase – S I
Asp23, alkaline shock protein 23 – S NI, I
Atl, autolysin ME, S ME, S I
ClpP, ATP-dependent Clp protease S S NI, I
Cna, collagen adhesin precursor ME, S – I
Coa, coagulase ME – NI, I
DeoD, purine nucleoside phosphorylase ME ME NI, I
Ear S S I
Eno, enolase S S NI, I
Fba, fructose bisphosphate aldolase S – NI, I
Fhs, formate tetrahydrofolate ligase ME, S ME, S I
Ftn, ferritin – S I
Gap, glyceraldehyde 3-phosphate dehydrogenase ME, S ME, S I
GlyA, serine hydroxymethyltransferase – S I
Gpi, glucose 6-phosphate isomerase ME ME NI, I
GuaB, inositol-monophosphate dehydrogenase ME – NI, I
Idh1, isocitrate dehydrogenase – S NI, I
Lip, lipase S S I
MW0525, hexulose 6-phosphate synthase – S I
MW0896, 2′-5′ RNA ligase – S NI, I
MW1795, hypothetical protein – S NI, I
MW1870, thioredoxin – S NI, I
PdhA, pyruvate dehydrogenase subunit A ME ME NI, I
PdhB, pyruvate dehydrogenase subunit B S S NI, I
Pgd, phosphogluconate dehydrogenase ME ME NI, I
Pgi, phosphoglucose isomerase S S NI, I
Plc, 1-phosphatidylinositol phosphodiesterase S S I
Pta, phosphate acetyltransferase – S I
RocD, ornithine aminotransferase S – NI, I
Sak, staphylokinase ME ME, S I
Sec3, staphylococcal enterotoxin C3 S – I
Seq, staphylococcal enterotoxin Q ME ME I
SodA, superoxide dismutase S S I
Spa, immunoglobulin-binding protein A ME, S ME, S NI, I
SspB, cysteine protease precursor ME, S ME, S I
Sulfatase S – NI, I
Tkt, transketolase S – I
TpiA, triosephosphate isomerase – ME I
Tsf, translation elongation factor Ts ME S I
Tuf, translation elongation factor Tu ME, S ME, S NI, I
Unknown 1 ME – I
Unknown 2 ME – I
Unknown 3 – ME I
Unknown 4 – ME I
Unknown 5 – ME I
Unknown 6 – ME I
a. Protein identities were obtained by overlay analysis as described under Experimental procedures. Results are representative of three
experiments using serum pooled from 10 to 15 mice.
ME, mid-exponential phase of growth; S, stationary phase of growth; NI, non-immune sera; I, immune sera.
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and characterization of many important S. aureus exopro-
teins, there is a noted paucity of information regarding
exoproteins produced by CA-MRSA strains.
Our analysis of MW2 (USA400) and LAC (USA300)
culture supernatants identiﬁed 250 exoproteins (out of
600+ resolved protein spots) between two phases of
growth in vitro, at present the single most comprehensive
Fig. 5. Production and distribution of selected
MW2 (USA400) virulence factors during
phagocytosis by human PMNs. Following
phagocytosis of MW2, aureolysin (Aur), SspA
and SspB were visualized by confocal
laser-scanning microscopy. White arrowheads
indicate bacteria. Yellow arrowheads indicate
areas enriched with the S. aureus protein of
interest. The image labelled ‘Merge’ illustrates
distribution of neutrophil actin-related protein
(ARP, green) and nuclei (blue). DIC,
differential interference contrast.
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MW2 and LAC exoproteins revealed key differences
between the strains (Fig. 3). These differences were not
due to differences in rate of growth between the strains,
because MW2 and LAC have essentially identical growth
curves in vitro (Fig. 1A). Although many of the differen-
tially abundant exoproteins, including Atl, Coa, Hla, Lip,
Mrp, Sak, Sek, Seq, Sec3, SspA, SspB and SplC, are
Fig. 6. Production and distribution of selected
LAC (USA300) virulence factors during
phagocytosis by human PMNs. Following
phagocytosis of LAC, Hla, SspA and SspB
were visualized by confocal laser-scanning
microscopy. Labelling for this ﬁgure is
otherwise identical to the legend for Fig. 5.
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the observed variances in protein levels relate to distinct
strain pathologies. For example, Cna is linked to necro-
tizing pneumonia (de Bentzmann et al., 2004) and there
were higher levels of this exoprotein in MW2 culture
supernatants (Fig. 3). MW2 is a strain known to cause
lethal pneumonia (Centers for Disease Control and Pre-
vention, 1999). Compared with MW2, more Hla was
present in LAC culture supernatants (7.5  1.8- and
9.2  1.8-fold more Hla at mid-exponential and stationary
phases of growth respectively). Consistent with that
observation, Hla appeared to accumulate more rapidly in
LAC-containing neutrophil phagosomes or was more
highly diffused in and around deteriorating PMNs after
phagocytosis of LAC compared with MW2 containing cells
(accumulation of Hla typically occurred by 180 min in
LAC-containing PMNs versus 240 min in those with
MW2). We recently found dramatic differences in patho-
physiology between MW2 and LAC in a mouse skin
infection/abscess model (Voyich et al., 2006). LAC pro-
duced rapid and pronounced dermonecrosis in infected
animals, whereas mice infected with MW2 developed
intact abscesses (Voyich et al., 2006). Thus, differences
in exoprotein abundance, such as that for Hla, may under-
lie the differences in strain pathology. Additional studies
are needed to test this hypothesis.
We used sera from mice infected with MW2 or LAC to
identify exoproteins made during infection in vivo (Fig. 4).
Previous serological proteome studies using strain COL
identiﬁed 15 immunogenic proteins made during human
infections, although only four of these proteins (alkaline
shock protein, hexose 6-phosphate synthase, PdhB and
Tuf) are common with our analysis (Table 2) (Vytvytska
et al., 2002). In more recent work, Clarke et al. used bac-
teriophage expression libraries to identify S. aureus anti-
gens produced during human infections (Clarke et al.,
2006). Several of those immunogenic proteins, i.e. cho-
rismate mutase (AroA), autolysin (Atl), Coa, Fhs, Gap,
transketolase (Tkt) and triosephosphate isomerase (Tpi),
were also identiﬁed as in vivo expressed S. aureus anti-
gens by our studies (Table 2). Our work revealed many
additional exoproteins produced during infection, such as
AhpC, Cna, Ear, ferritin (Ftn), Lip, Plc, phosphate acetyl-
transferase (Pta), Sak, Sec3, Seq and SspB (Fig. 4).
Importantly, these proteins were immunoreactive only with
sera from MW2- or LAC-infected animals (as opposed to
sera from uninfected animals). Variances in antigenic exo-
proteins between MW2 and LAC are likely explained in
part by differences in gene content or phase of growth
used to test antigenicity (Fig. 4). The relative importance
of these in vivo expressed proteins remains to be
determined.
At least four of the exoproteins identiﬁed by our pro-
teomic analysis (Aur, Hla, SspA and SspB) were pro-
duced within phagosomes of human neutrophils
following uptake (phagocytosis) (Figs 5 and 6). These
ﬁndings are notable because MW2 and LAC are known
to cause rapid lysis of PMNs (Voyich et al., 2005) and
the factors responsible for the dramatic host cell lysis
remain elusive (Voyich et al., 2006). Consistent with
these data, we determined previously that the gene
encoding Hla was upregulated during phagocytosis
(Voyich et al., 2005). Although our studies do not dem-
onstrate that Aur, Hla, SspA and SspB are directly
related to the observed PMN lysis, increased accumula-
tion of these virulence determinants accompanied initial
stages of neutrophil destruction (Figs 5 and 6).
The S. aureus genome consists of ~2600 proteins of
which more than 40% have no similarity to proteins of
known function (Kuroda et al., 2001). Moreover, 33% of
identiﬁed proteins are unique to S. aureus (Kuroda et al.,
2001). Therefore, it is not surprising that 8.5% of the
proteins identiﬁed in our study have no known function
(Fig. 1). Some of these exoproteins are of signiﬁcant inter-
est based upon homology to known S. aureus proteins
(e.g. SAUSA300_0407 as an exotoxin homologue) or
given their location within the genome (Table 1 and
Table S1). Several exoproteins identiﬁed by our analysis
are putative exported or surface proteins, e.g.
SAUSA300_0408 and MW0355 (rather than metabolism
enzymes, etc.) and also require characterization in the
context of CA-MRSA pathogenesis (Fig. 3).
We used a proteomics-based approach to generate a
comprehensive view of exoproteins made by prominent
CA-MRSA strains, including identiﬁcation of proteins that
are immunogenic and thus produced during infection in
vivo. Identiﬁcation of these exoproteins is an important
ﬁrst step towards development of vaccines, prophylactics,
and enhanced therapeutics designed to control
CA-MRSA infections.
Experimental procedures
Growth of S. aureus and generation of culture
supernatants
Staphylococcus aureus strains MW2 (USA400) (Baba et al.,
2002) and LAC (USA300-0114) (Kazakova et al., 2005; Miller
et al., 2005; Voyich et al., 2005; Diep et al., 2006) were cultured
in tryptic soy broth containing 0.25% dextrose (TSB, Becton,
Dickenson, and Company, Franklin Lakes, NJ) ﬁltered sequen-
tially through 10 kDa cut-off and 0.22 mm ﬁlters. Cultures were
inoculated with a 1:200 dilution of overnight culture (500 mlo f
culture into 100 ml of TSB in a 1 l ﬂask) and incubated at 37°C
with shaking (250 rpm). All strains were cultured to mid-
exponential (OD600 = 0.75) or stationary (OD600 = 2.0) phases of
growth and placed on ice until used. Bacteria were removed from
culture media by two sequential rounds of centrifugation at
2851 g for 10 min at 4°C. This procedure yielded clariﬁed culture
supernatants for subsequent proteomic analyses.
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proteins
Precipitation of proteins from clariﬁed culture supernatants was
performed in polypropylene ﬂasks to reduce protein loss. One
hundred millilitres of clariﬁed supernatant was added to 300 ml of
100% ethanol (Molecular Grade, Sigma-Aldrich, St Louis, MO)
and chilled at -20°C overnight. Precipitated protein was trans-
ferred to Oakridge centrifuge tubes and sedimented by centrifu-
gation at 27 216 g for 30 min at 4°C. To optimize yield, protein in
polypropylene ﬂasks (residual) and centrifuge tubes was air-dried
for approximately 1 h. Protein in the ﬂasks were solubilized with
3 ml of 2-D solubilization solution (7 M urea, 2 M thiourea, 4%
CHAPS) with gentle swirling. These samples were transferred to
Oakridge tubes containing precipitated protein pellets and swirled
gently to dissolve pellets. Polypropylene ﬂasks were rinsed with
an additional 600 ml of 2-D solubilization solution.
Culture supernatant proteins were clariﬁed further with a
second precipitation in 30% triﬂuoroacetic acid (Sigma-Aldrich)
and incubated on ice for a minimum of 30 min. Precipitated
proteins were collected by centrifugation at 14 100 g f o r5m i na t
room temperature. The protein pellet was dispersed by vortexing
in 25 ml of distilled H2O for 10 s followed by the addition of 1 ml of
acetone (-20°C). Proteins were washed in acetone for a
minimum of 30 min at -20°C and then pelleted by centrifugation
at 14 100 g for 5 min at room temperature. Proteins were air dried
for ~1 h or until pellets appeared dry. Pellets were solubilized
in 400 ml of Destreak Rehydration Solution (GE Healthcare,
Piscataway, NJ) containing tributylphosphine (200 mM) and
ampholytes (pH 3–10, 4 mlo f1 0 0 ¥ solution) (Bio-Rad, Hercules,
CA) at room temperature for 1 h with constant swirling. Samples
were used immediately or stored brieﬂy at -20°C.
Isolation of human neutrophils
Human polymorphonuclear leucocytes were isolated from fresh
venous blood of healthy individuals using a published method
(Kobayashi et al., 2002; Burlak et al., 2006). Studies were per-
formed in accordance with a protocol approved by the Institu-
tional Review Board for Human Subjects, National Institute of
Allergy and Infectious Diseases. PMN preparations typically con-
tained ~94% neutrophils, with the remaining cells being predomi-
nantly eosinophils. All reagents used contained < 2 5 . 0p gm l
-1
endotoxin (Limulus Amebocyte Lysate assay, Fisher Scientiﬁc,
Suwannee, GA).
Neutrophil phagocytosis
MW2 and LAC were cultured to mid-exponential phase of growth
and phagocytosis experiments were performed with serum-
opsonized bacteria as described (Kobayashi et al., 2003; Voyich
et al., 2005).At the indicated times, phagocytosis was terminated
either by chilling PMNs on ice or adding cold paraformaldehyde
(4%) to assay wells.
Generation of immune sera
Female Crl:SKH1-hrBR mice (Charles River Laboratories, Wilm-
ington, MA) were anaesthetized with isoﬂurane and inoculated
with 50 ml of DPBS containing 107 cfu of MW2 or LAC by subcu-
taneous injection in the right ﬂank. Abscesses typically formed
within 4 days and resolved 14 days after infection (Voyich et al.,
2006).At 28 days post infection, mice were euthanized and blood
was collected from 10 to 15 mice to prepare pooled immune
serum. Blood from uninfected animals was processed in parallel
(non-immune serum). All studies conformed to guidelines set
forth by the National Institutes of Health and were reviewed and
approved by the Animal Use Committee at Rocky Mountain
Laboratories, NIAID.
Isoelectric focusing and second-dimension SDS-PAGE
Culture supernatant proteins were precipitated in cold acetone
and then solubilized with isoelectric focusing (IEF) buffer (7%
urea, 2% thiourea, 4% CHAPS and 200 mM tributylphosphine)
as described (Burlak et al., 2006). Protein concentration was
measured with the 2-D Quant kit (GE Healthcare) and puriﬁed
proteins were stored at -80°C.
For IEF, samples were treated with Destreak Rehydration solu-
tion (25% of total sample volume) (GE Healthcare), 200 mM
tributylphosphine and 1% ampholytes. IEF was performed with
11 cm IPG Ready Strips for 40 kVh. IPG Ready Strips were
rehydrated actively at 50 V overnight prior to ﬁrst dimension
separation. Moistened ﬁlter paper wicks (Whatman no. 1 paper,
Whatman, Florham Park, NJ) were added between each elec-
trode and strip prior to focusing (after rehydration). Wicks were
changed four times in the ﬁrst 4 h of IEF, after which the voltage
was maintained at 8000 V (11 cm IPG Ready Strips). Following
IEF, IPG Ready Strips were stored at -80°C until used for
SDS-PAGE.
Second-dimension SDS-PAGE was performed essentially as
described (Burlak et al., 2006), except electrophoresis was per-
formed at 50 mA per gel until the dye front reached the bottom of
each gel (~1 h for 11 cm gels). Protein spots were excised and
peptides were prepared for ADI-MS/MS analysis as described
previously for liquid chromatography-tandem mass spectrometry
(LC-MS/MS) (Burlak et al., 2006). For simplicity, the combination
of IEF and second-dimension SDS-PAGE is abbreviated as
2-DGE.
Mass spectrometry
Peptide samples (tryptic digests, as described/referenced above)
were analysed by automated direct infusion (ADI) using
Nanomate (Advion BioSciences, Ithaca, NY), an automated
chip-based nano-electrospray interface source, coupled to a
quadrupole-time of ﬂight mass spectrometer, QStarXL MS/MS
System (Applied Biosystems/Sciex, Framingham, MA).
Computer-controlled data-dependent automated switching to
MS/MS provided peptide sequence information. AnalystQS soft-
ware (Applied Biosystems/Sciex) was used for data acquisition.
Data processing and databank searching were performed with
Mascot software version 2.1 (Matrix Science, Beachwood, OH).
The National Center for Biotechnology Information non-
redundant protein database (NCBInr, updated 12 May, 2006 at
18:01:48 GMT), National Library of Medicine, NIH was used for
the search analysis. Search criteria were limited to double- and
triple-charge ions and included monoisotopic masses, analysis of
peptides for carbamidomethylation and/or propionamidylation of
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of 0.2 Da and 0.8 Da respectively, and a maximum of one missed
tryptic cleavage. Signiﬁcance threshold for positive identiﬁcation
was determined by the Mascot Search program.
Amino acid sequence analysis
Proteins involved in virulence/defence mechanisms, stress
response proteins, toxins, haemolysins and proteins of unknown
function were evaluated for presence of an LPXTG motif, which
predicts a cell wall anchor, and/or for sequences that predict an
N-terminal signal peptide or transmembrane region(s). We used
the NCBInr database to query the full sequence of each protein
identiﬁed by ADI/MS/MS for the presence of LPXTG motifs. The
presence of membrane spanning domains and N-terminal signal
peptide sequences was deduced by searching protein
sequences with PSORT software provided by the PSORT WWW
server (http://psort.nibb.ac.jp/). Although none of the 20 hypo-
thetical proteins identiﬁed in this study contain LPXTG motifs,
eight proteins contain probable N-terminal signal peptide
sequences and ﬁve have predicted transmembrane regions
(Table 1 and Table S1).
In addition, sequences of the hypothetical proteins were com-
pared to 902 genomes (Bacterial, Archaea, Viral, and Eukarya)
using NCBI and ERGO, a curated NIAID database containing
public and proprietary DNA.
SDS-PAGE and immunoblotting
Proteins were separated by SDS-PAGE, transferred to nitrocel-
lulose membranes, and membranes were blocked with 10%
normal goat serum in Tris buffered saline 150 mM NaCL, 50 mM
Tris base, pH 7.5, 1% Tween 20 and 0.02% sodium azide
(Sigma-Aldrich) overnight at 4°C. Blots were probed with immune
or non-immune mouse sera for 1–2 h at ambient temperature or
overnight at 4°C. Blots were washed in buffer containing 250 mM
NaCl, 10 mM Hepes and 2% Tween 20 (Sigma-Aldrich) and
incubated with secondary antibodies conjugated to horseradish
peroxidase for 1–2 h at ambient temperature. Immunoreactive
proteins were visualized with enhanced chemiluminescence
(SuperSignal West Pico, Pierce Biotechnology, Rockford, IL)
using Kodak X-Omat ﬁlm (Eastman Kodak, Rochester, NY).
Immunoﬂuorescence and confocal laser-scanning
microscopy
Acid washed coverslips (No. 1, 13 mm, round) were ﬂamed and
coated with 100% normal human serum in 24 well tissue culture
plates for 1 h. Coverslips were washed twice with DPBS and
synchronized phagocytosis was performed in 24 well plates as
described above. Fixed PMNs were washed three times in DPBS
and then permeabilized with 0.2% Triton X-100 for 5 min. After
three more washes in DPBS, cells were incubated with blocking
buffer (DPBS containing 5% BSA, 0.02% sodium azide) for 1 h.
Samples were labelled with a 1:1000 dilution of rabbit antiserum
containing antibodies speciﬁc for Hla (Sigma-Aldrich), SspA,
SspB, Aur and 2 mgm l
-1 of goat polyclonal antibodies speciﬁc for
human actin-related protein 2 mgm l
-1 (Santa Cruz Biotechnolo-
gies, Santa Cruz, CA) overnight at 4°C. Samples were washed
and subsequently labelled with donkey anti-rabbit antibody con-
jugated with phycoerythrin 1:1000 (Jackson Immunoresearch,
West Grove, PA) or donkey anti-goat antibody conjugated to
AlexaFluor488 (1:1000) (Molecular Probes, Eugene, OR). PMNs
were stained with DAPI (300 nM in DPBS, Molecular Probes) and
DRAQ5 (1.25 mM in DPBS, Biostatus Limited, Leicestershire,
UK) prior to mounting coverslips onto slides. Slides were analy-
sed with a Zeiss LSM510 confocal laser-scanning microscope
coupled to an Axiovert 200M inverted microscope (Carl Zeiss,
Thornwood, NY). Images were acquired using a 100¥ Plan-
Apochromat oil immersion objective (1.4 NA) at 512 ¥ 512 pixel
resolution with 2.7¥ digital magniﬁcation. Images were adjusted
equally for brightness and contrast in Adobe Photoshop CS
(Adobe Systems Incorporated, San Jose, CA).
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